Future Fund LLC Takes Position in RxSight, Inc. $RXST

Future Fund LLC bought a new position in shares of RxSight, Inc. (NASDAQ:RXST) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 46,749 shares of the company’s stock, valued at approximately $608,000. Future Fund LLC owned about 0.12% of RxSight as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of RXST. Bessemer Group Inc. acquired a new stake in RxSight during the 2nd quarter worth about $33,000. State of Wyoming grew its position in RxSight by 91.5% in the 1st quarter. State of Wyoming now owns 2,062 shares of the company’s stock valued at $52,000 after purchasing an additional 985 shares during the period. CWM LLC grew its holdings in shares of RxSight by 614.1% during the second quarter. CWM LLC now owns 4,520 shares of the company’s stock valued at $59,000 after buying an additional 3,887 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of RxSight by 161.2% during the first quarter. Russell Investments Group Ltd. now owns 4,091 shares of the company’s stock valued at $103,000 after buying an additional 2,525 shares during the last quarter. Finally, AlphaQuest LLC increased its position in shares of RxSight by 66.0% during the first quarter. AlphaQuest LLC now owns 8,443 shares of the company’s stock worth $213,000 after acquiring an additional 3,357 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $9.37 on Monday. RxSight, Inc. has a 1 year low of $6.32 and a 1 year high of $49.25. The company has a market capitalization of $385.29 million, a PE ratio of -10.65 and a beta of 1.16. The business has a fifty day moving average price of $8.78 and a two-hundred day moving average price of $10.72.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.15. The company had revenue of $30.34 million for the quarter, compared to the consensus estimate of $25.63 million. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. The firm’s quarterly revenue was down 31.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.16) EPS. RxSight has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Morgan Stanley downgraded RxSight from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $20.00 to $9.00 in a research note on Tuesday, July 15th. Zacks Research upgraded RxSight from a “strong sell” rating to a “hold” rating in a report on Monday, September 8th. UBS Group dropped their price objective on RxSight from $16.00 to $8.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company lifted their price objective on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of RxSight in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, RxSight presently has a consensus rating of “Reduce” and a consensus target price of $9.56.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.